Open AccessProlongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma
Author(s) -
Wojciech Rogowski,
Przemysław Będkowski
Publication year - 2021
Publication title -
oncoreview
Language(s) - English
Resource type - Journals
eISSN - 2450-6125
pISSN - 2353-852X
DOI - 10.24292/01.or.123150721
Subject(s) - medicine , irinotecan , pancreatic cancer , oncology , stage (stratigraphy) , quality of life (healthcare) , adenocarcinoma , chemotherapy , disease , life quality , cancer , surgery , colorectal cancer , paleontology , nursing , biology , physical therapy
Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2].
This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.